|
|
 |
|
Viewing report
|
|
|
|
Macular Edema - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, Dec 2010, Pages: 39
“Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global macular edema therapeutics market. The report identifies the key trends shaping and driving the global macular edema therapeutics market. The report also provides insight on the competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global macular edema therapeutics market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.
The authors valued the global macular edema therapeutics market at $3.3 billion in 2009. It is expected to grow to $6.9 billion with a Compound Annual Growth Rate (CAGR) of 9.5% by 2017. This growth is primarily attributed to the increase in the prevalence and incidence rates of diabetes across the world. Macular edema is a slowly progressing disease and diabetes is cited as the main cause. The growth in the market will be supported and driven by the increased use of the newly approved drugs.
The authors found that current competition in the macular edema market is strong, particularly due to the increased competition among the off-label products, which are the most commonly used treatments by ophthalmologists, and between the newly approved drugs. There are other treatment options available such as thermal lasers, photocoagulation therapy and surgical options such as vitrectomy, which are believed to offer a better safety profile among patients. Despite these, the market for macular edema therapeutics is dominated by off-label products and partly by newly approved products. Some of the products which were being used as off-label indications are currently undergoing clinical studies to validate their safety and efficacy profiles and to gain approval by the regulatory authorities for prescription usage. The market is therefore competitive and is expected to witness a price war in the coming years
Scope
The scope of the report includes:
- Annualized global macular edema therapeutics market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The pipeline is primarily dominated by anti-VEGF antibodies, plasma kallikrein-kinin inhibitor and corticosteroids, which combined hold a share of 40% of the total pipeline.
- Analysis of the current and future market competition in the global macular edema therapeutics market. Key future market players covered are pSivida, Roche/Genentech, Pfizer and iCo Therapeutics.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with macular edema therapeutics market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global macular edema therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global macular edema therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global macular edema therapeutics market landscape? – Identify, understand and capitalize.'
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market
Diabetic Retinopathy - Global Strategic Business Report
Diabetic Macular Edema - Pipeline Review, Q4 2010
Macular Degeneration Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Diabetic Macular Edema - Pipeline Review, Q2 2011
The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
Macular Edema - Pipeline Review, H1 2012
Edema - Pipeline Review, Q3 2011
Choroidal Neovascularization (CNV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
|
|
|
|
